Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Companies will study the combination of Ascentage's APG-2575 and Acerta's CALQUENCE® (acalabrutinib), evaluating the efficacy and safety of this combination therapy in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Lead Product(s): Lisaftoclax,Acalabrutinib
Therapeutic Area: Oncology Product Name: APG-2575
Highest Development Status: Phase I/ Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Ascentage Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 21, 2020